Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “We are very excited to have dosed the first participant in this highest dose level cohort of our theranostic neuroblastoma trial in the US, having successfully completed cohort 3 very recently. We hope that the increase in administered activity between cohorts 3 and cohort 4 will have a significant impact on radiation-sensitive disease, such as neuroblastoma, and we look forward to generating the data from the 375MBq/kg body weight dose.
